- Home
- HKD vs MYGN Comparison
HKD vs MYGN Comparison
Compare HKD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HKD | MYGN |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.3M | 481.6M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HKD | MYGN |
|---|---|---|
| Price | $1.66 | $4.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 636.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.26 | $3.76 |
| 52 Week High | $5.47 | $10.32 |
Technical Indicators
Market Signals| Indicator | HKD | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 45.81 |
| Support Level | $1.60 | $3.93 |
| Resistance Level | $1.68 | $5.63 |
| Average True Range (ATR) | 0.15 | 0.41 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 33.78 | 48.76 |
Price Performance
Historical ComparisonAbout HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.